118 related articles for article (PubMed ID: 2452868)
1. The accumulation mechanism of cationic mitomycin C-dextran conjugates in the liver: in-vivo cellular localization and in-vitro interaction with hepatocytes.
Nakane S; Matsumoto S; Takakura Y; Hashida M; Sezaki H
J Pharm Pharmacol; 1988 Jan; 40(1):1-6. PubMed ID: 2452868
[TBL] [Abstract][Full Text] [Related]
2. Cellular interaction and in vitro antitumor activity of mitomycin C-dextran conjugate.
Matsumoto S; Yamamoto A; Takakura Y; Hashida M; Tanigawa N; Sezaki H
Cancer Res; 1986 Sep; 46(9):4463-8. PubMed ID: 2425952
[TBL] [Abstract][Full Text] [Related]
3. Disposition of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate, in the perfused rat liver.
Sato K; Itakura K; Nishida K; Takakura Y; Hashida M; Sezaki H
J Pharm Sci; 1989 Jan; 78(1):11-6. PubMed ID: 2468759
[TBL] [Abstract][Full Text] [Related]
4. Biliary excretion of mitomycin C dextran conjugates in relation to physicochemical characteristics of carrier dextran.
Hashida M; Atsumi R; Nishida K; Nakane S; Takakura Y; Sezaki H
J Pharmacobiodyn; 1990 Jul; 13(7):441-7. PubMed ID: 1705289
[TBL] [Abstract][Full Text] [Related]
5. Disposition and tumor localization of mitomycin C-dextran conjugates in mice.
Takakura Y; Takagi A; Hashida M; Sezaki H
Pharm Res; 1987 Aug; 4(4):293-300. PubMed ID: 2470072
[TBL] [Abstract][Full Text] [Related]
6. Disposition and pharmacokinetics of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate, in the rat.
Hashida M; Kato A; Takakura Y; Sezaki H
Drug Metab Dispos; 1984; 12(4):492-9. PubMed ID: 6148218
[TBL] [Abstract][Full Text] [Related]
7. Enhanced lymphatic delivery of mitomycin C conjugated with dextran.
Takakura Y; Matsumoto S; Hashida M; Sezaki H
Cancer Res; 1984 Jun; 44(6):2505-10. PubMed ID: 6202398
[TBL] [Abstract][Full Text] [Related]
8. Disposition characteristics of mitomycin C-dextran conjugate in normal and tumor-bearing muscles of rabbits.
Atsumi R; Endo K; Kakutani T; Takakura Y; Hashida M; Sezaki H
Cancer Res; 1987 Nov; 47(21):5546-51. PubMed ID: 2444332
[TBL] [Abstract][Full Text] [Related]
9. Urinary excretion characteristics of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate.
Takakura Y; Kato A; Hashida M; Honda K; Arimoto A; Satomura K; Sezaki H
J Pharmacobiodyn; 1985 May; 8(5):357-64. PubMed ID: 2413196
[TBL] [Abstract][Full Text] [Related]
10. Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver.
Nishida K; Mihara K; Takino T; Nakane S; Takakura Y; Hashida M; Sezaki H
Pharm Res; 1991 Apr; 8(4):437-44. PubMed ID: 1714579
[TBL] [Abstract][Full Text] [Related]
11. [Topical application of mitomycin C conjugated with dextran (MMC-D): a high molecular weight derivative of mitomycin C].
Honda K; Satomura K; Hashida M; Sezaki H
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):530-5. PubMed ID: 2408576
[TBL] [Abstract][Full Text] [Related]
12. Mitomycin C-dextran conjugate: a novel high molecular weight pro-drug of mitomycin C.
Kojima T; Hashida M; Muranishi S; Sezaki H
J Pharm Pharmacol; 1980 Jan; 32(1):30-4. PubMed ID: 6102123
[TBL] [Abstract][Full Text] [Related]
13. In vivo drug release and antitumor characteristics of water-soluble conjugates of mitomycin C with glycol-chitosan and N-succinyl-chitosan.
Sato M; Onishi H; Takahara J; Machida Y; Nagai T
Biol Pharm Bull; 1996 Sep; 19(9):1170-7. PubMed ID: 8889036
[TBL] [Abstract][Full Text] [Related]
14. Specificity of antisera produced against mitomycin C.
Fujiwara K; Saikusa H; Kitagawa T; Takahashi S; Konishi Y
Cancer Treat Rep; 1983 Dec; 67(12):1079-84. PubMed ID: 6418380
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoural injection.
Nomura T; Saikawa A; Morita S; Sakaeda Kakutani T; Yamashita F; Honda K; Takakura Y; Hashida M
J Control Release; 1998 Mar; 52(3):239-52. PubMed ID: 9743445
[TBL] [Abstract][Full Text] [Related]
16. Biological properties of conjugates of mitomycin C with estradiol benzoate and estradiol: their stability characteristics in biological media and their binding abilities to estrogen receptor.
Ishiki N; Onishi H; Machida Y
Biol Pharm Bull; 1997 Oct; 20(10):1096-102. PubMed ID: 9353572
[TBL] [Abstract][Full Text] [Related]
17. Contrasting molecular cytotoxic mechanisms of mitomycin C and its two analogs, BMY 25282 and BMY 25067, in isolated rat hepatocytes.
Silva JM; Khan S; O'Brien PJ
Biochem Pharmacol; 1993 Jun; 45(11):2303-9. PubMed ID: 8517871
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of mitomycin C uptake by isoproterenol in rat ascites hepatoma.
Miyamoto K; Matsunaga T; Waki Y; Koshiura R
J Pharmacobiodyn; 1986 May; 9(5):453-9. PubMed ID: 3020222
[TBL] [Abstract][Full Text] [Related]
19. Circumvention of deficient activation in mitomycin C-resistant human colonic carcinoma cells by the mitomycin C analogue BMY25282.
Chakrabarty S; Danels YJ; Long BH; Willson JK; Brattain MG
Cancer Res; 1986 Jul; 46(7):3456-8. PubMed ID: 3754788
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of mitomycin-C in plasma and tumor tissue of cervical cancer patients and in selected tissues of female rats.
Malviya VK; Young JD; Boike G; Gove N; Deppe G
Gynecol Oncol; 1986 Oct; 25(2):160-70. PubMed ID: 3019843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
